Johnson & Johnson (NYSE:JNJ) Shares Sold by Resonant Capital Advisors LLC

Resonant Capital Advisors LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 6.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,999 shares of the company’s stock after selling 1,789 shares during the period. Resonant Capital Advisors LLC’s holdings in Johnson & Johnson were worth $3,918,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. First Citizens Financial Corp boosted its stake in Johnson & Johnson by 8.1% in the third quarter. First Citizens Financial Corp now owns 8,599 shares of the company’s stock valued at $1,339,000 after acquiring an additional 645 shares during the period. PineStone Asset Management Inc. boosted its stake in Johnson & Johnson by 190.5% in the third quarter. PineStone Asset Management Inc. now owns 1,494,978 shares of the company’s stock valued at $232,843,000 after acquiring an additional 980,297 shares during the period. Buckingham Capital Management Inc. boosted its stake in Johnson & Johnson by 6.5% in the third quarter. Buckingham Capital Management Inc. now owns 10,703 shares of the company’s stock valued at $1,667,000 after acquiring an additional 651 shares during the period. McKinley Carter Wealth Services Inc. boosted its stake in Johnson & Johnson by 0.6% in the third quarter. McKinley Carter Wealth Services Inc. now owns 18,860 shares of the company’s stock valued at $2,937,000 after acquiring an additional 114 shares during the period. Finally, OneAscent Financial Services LLC acquired a new position in Johnson & Johnson in the third quarter valued at approximately $838,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $148.53 on Thursday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock has a market cap of $357.92 billion, a price-to-earnings ratio of 9.26, a PEG ratio of 2.46 and a beta of 0.53. The stock’s 50 day moving average price is $155.69 and its 200 day moving average price is $155.47. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.68 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.34%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 29.68%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JNJ. Raymond James lifted their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada cut their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.